Pyrrolopyrimidine compounds and their uses

US8685980B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• ASTEX THERAPEUTICS LIMITED · GB

Inventors

• Gilbert Ebai Besong · Bad Dürkheim, DE
• Christopher Thomas Brain · North Reading, US
• Clinton A. BROOKS · Smyrna, US
• Miles Stuart Congreve · Cambridge, GB
• Claudio Dagostin · Cambridge, GB
• Guo He · Lexington, US
• Ying Hou · Everett, US
• Steven Howard · Cambridge, GB
• Yue Li · Shanghai, CN
• Yipin Lu · Emeryville, US
• Paul Mortenson · Cambridge, GB
• Troy Douglas Smith · Nashua, US
• Moo Je Sung · Belmont, US
• Steven John Woodhead · San Diego, US
• Wojciech Wrona · Cambridge, US
• Bharat Lagu · Maywood, US

Key dates

• Filing date: Aug 20, 2009
• Grant date: Apr 1, 2014
• Expiry date: May 25, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.